Nanoscope Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

DALLAS, Jan. 9, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced that Chief Executive Officer, Sulagna Bhattacharya, will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 4:00 p.m. PT, in San Francisco. 

Ms. Bhattacharya's presentation will highlight Nanoscope's progress towards a near-term Biologics License Application (BLA) submission and the subsequent path to the potential launch of its Multi-Characteristic Opsin (MCO-010) product, first-to-market restorative treatment for patients with vision loss from Retinitis Pigmentosa (RP), if approved. She will also discuss the advancement of the Company's Adeno-associated virus (AAV) pipeline program for Stargardt macular degeneration to a planned single registrational Phase 3 trial, and the progression of a non-viral platform program for geographic atrophy (GA) to a first-in-human trial. 

Management will be available for in-person meetings during the conference. To schedule a meeting, please contact [email protected].

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in Q1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial in Q1 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready non-viral laser-delivered MCO-020 asset for GA, as well as an IND-ready AAV asset for Leber Congenital Amaurosis.

Investor Contact:
Argot Partners
212-600-1902
[email protected]

SOURCE Nanoscope Therapeutics